Objective: Given that patients with nonedialysis-dependent chronic kidney disease (NDD-CKD) have a disproportionately higher prevalence of hypothyroidism compared with their non-CKD counterparts, we sought to determine the association between thyroid status, defined by serum thyrotropin (TSH) levels, and mortality among a national cohort of patients with NDD-CKD. Patients and Methods: Among 227,422 US veterans with stage 3 NDD-CKD with 1 or more TSH measurements during the period October 1, 2004, to September 30, 2012, we first examined the association of thyroid status, defined by TSH categories of less than 0.5, 0.5 to 5.0 (euthyroidism), and more than 5.0 mIU/L, with all-cause mortality. We then evaluated 6 granular TSH categories: less than 0.1, 0.1 to less than 0.5, 0.5 to less than 3.0, 3.0 to 5.0, more than 5.0 to 10.0, and more than 10.0 mIU/L. We concurrently examined thyroid status, thyroid-modulating therapy, and mortality in sensitivity analyses. . Granular examination of thyroid status showed that incrementally higher TSH levels of 3.0 mIU/L or more were associated with increasingly higher mortality in baseline and time-dependent analyses, and TSH categories of less than 0.5 mIU/L were associated with higher mortality (reference, 0.5-<3.0 mIU/L) in baseline analyses. In time-dependent analyses, untreated and undertreated hypothyroidism and untreated hyperthyroidism were associated with higher mortality (reference, spontaneous euthyroidism), whereas hypothyroidism treated-to-target showed lower mortality. Conclusion: Among US veterans with NDD-CKD, high-normal TSH (!3.0 mIU/L) and lower TSH (<0.5 mIU/L) levels were associated with higher death risk. Interventional studies identifying the target TSH range associated with the greatest survival in patients with NDD-CKD are warranted. 
T hyroid dysfunction is a highly prevalent yet underrecognized endocrine complication affecting a large proportion of patients with chronic kidney disease (CKD). 1, 2 Several large population-based studies found that hypothyroidism is increasingly more common with incrementally impaired kidney function. [3] [4] [5] [6] [7] Data from 14,623 participants in the Third National Health and Nutrition Examination Survey have shown that the prevalence of hypothyroidism was 5.4%, 10.9%, 20.4%, 23.0%, and 23.1% among those with estimated glomerular filtration rates (eGFRs) of 90 or more, 60 to 89, 45 to 59, 30 to 44, and less than 30 mL/min/1.73 m 2 , respectively. 5 More recently, among a large national cohort of 461,607 US veterans with stage 3 to 5 CKD, for every 10 mL/min/1.73 m 2 decrement in eGFR, there was an 18% higher likelihood of hypothyroidism. 6 Although there are comparatively fewer reports in patients with end-stage renal disease (ESRD), a similarly high prevalence (w22%) of hypothyroidism has been observed in large dialysis cohorts. 8, 9 In the general population, adverse cardiovascular sequelae may result from untreated hypothyroidism (eg, altered cardiac structure and function, endothelial dysfunction, dyslipidemia, accelerated atherosclerosis, and electrophysiologic changes [10] [11] [12] [13] ) as well as with hyperthyroidism (eg, atrial fibrillation, heart failure, and coronary ischemia 12, 14 ) . Hence, this high burden of thyroid dysfunction may have an important bearing on the survival of patients with kidney disease, who suffer from disproportionately high cardiovascular death risk (w40% of deaths 15, 16 ). Indeed, a growing body of evidence reports that hypothyroidism, defined by elevated serum thyrotropin (TSH) levels as the most sensitive and specific clinical goal standard of thyroid function assessment, [17] [18] [19] is associated with higher mortality in some, 8, 9, 20, 21 but not all, 22 studies of the dialysis population. Recent data have also corroborated a link between hyperthyroidism and sudden cardiac death among hemodialysis patients from the Die Deutsche Diabetes Dialyse Studie (also known as the 4D Trial), 22 and with all-cause mortality in a national peritoneal dialysis cohort. 9 However, little is known about the association between thyroid status and mortality risk in patients with CKD who are nonedialysis-dependent (NDD).
To address this knowledge gap, we conducted a study examining the relationship between thyroid status and mortality risk among a large longitudinal cohort of US veterans with stage 3 CKD and repeated measures of serum TSH over time. We hypothesized that both higher and lower TSH levels were independently associated with higher mortality risk in this nationally representative NDD-CKD cohort. On the basis of previous studies of thyroid status and mortality in the dialysis population, 8, 20 we were also specifically interested in examining the TSH threshold of 3.0 mIU/L or more as the level above which higher mortality is observed in patients with NDD-CKD.
PATIENTS AND METHODS

Source Cohort
We conducted a historical cohort study using data from the "Racial and Cardiovascular Risk Anomalies in Chronic Kidney Disease" study, constructed to examine US veterans with incident CKD who underwent care within the Veterans Affairs (VA) health care system over the period of October 1, 2004 , to September 30, 2012. [23] [24] [25] [26] Patients were included provided that they underwent at least 1 TSH measure anytime during the study period; had the requisite covariates needed to calculate eGFR (eg, age, race, and serum creatinine) within 1 year of study entry (ie, date of the baseline TSH); and had stage 3 CKD (eGFR, 30-<60 mL/min/1.73 m 2 ) at study entry. Patients were excluded if they were receiving dialysis at the time of study entry; had an improbable TSH level (ie, 0 mIU/L); or had an implausible follow-up time value. The study was approved by the institutional review committees of the Memphis and Tibor Rubin VA Medical Centers.
Exposure Ascertainment
The exposure of interest was thyroid status defined by serum TSH concentration (irrespective of treatment status). In primary analyses, we examined thyroid status categorized as TSH levels of more than 5.0, 0.5 to 5.0, and less than 0.5 mIU/L (based on thresholds used in the general population for ascertainment of hypothyroidism, euthyroidism, and hyperthyroidism, respectively). 8, 9, 17 In secondary analyses, we examined thyroid status using more granular categorizations of TSH, defined according to the usual TSH ranges for these designations: overt-hypothyroid (>10.0 mIU/L), subclinical-hypothyroid (>5.0-10.0 mIU/L), high-normal (3.0-5.0 mIU/L), low-normal (0.5-<3.0 mIU/L), subclinical-hyperthyroid (0.1-<0.5 mIU/L), and overt-hyperthyroid (<0.1 mIU/L) ranges. 8, 9, 20 We were specifically interested in the TSH threshold of 3.0 mIU/L or more as the level above which higher mortality may be observed. 8, 20 We also examined TSH as a continuous predictor of mortality using restricted cubic spline analyses with knots defined at the 33rd and 66th percentiles of observed TSH values.
We first examined the association between baseline thyroid status and all-cause mortality to ascertain long-term associations of thyroid status with death risk. 27 Given that underlying illness may influence serum TSH levels in the absence of true thyroid functional disease while also increasing patients' risk of death, we conducted 2 types of sensitivity analyses of baseline thyroid status and mortality risk: (1) analyses that included a 30-day lag period between the date of baseline TSH measurement and start of follow-up time to minimize bias from reverse causation, 20 and (2) analyses that examined the association of incident hypothyroidism and incident hyperthyroidism (defined as those who had a baseline TSH level that was within the reference range [0.5-5.0 mIU/L] and had a second TSH level that was >5.0 mIU/L and <0.5 mIU/L, respectively) with mortality.
We then examined the association between time-dependent thyroid status and all-cause mortality, in which thyroid status was time-updated with repeated TSH measures to ascertain shortterm associations of thyroid status with death risk, and to account for changes in thyroid status over time. 27 The median (interquartile range [IQR] ) and minimum-maximum number of TSH measurements contributed by each patient was 4 (2-6) and 1-54, respectively.
To determine the impact of thyroidmodulating therapy on the association of thyroid status with mortality, we compared death risk across the following categories that concurrently considered patients' TSH levels and medication status: hypothyroid overtreated (TSH<0.5 mIU/L, on thyroid hormone replacement), hypothyroid untreated (TSH>5.0 mIU/ L, not on thyroid hormone replacement), hypothyroid undertreated (TSH>5.0 mIU/L, on thyroid hormone replacement), hypothyroid treatedto-target (TSH¼0.5-5.0 mIU/L, on thyroid hormone replacement), spontaneously euthyroid (TSH¼0.5-5.0 mIU/L, not on thyroid hormone replacement or antithyroid medication), hyperthyroid undertreated (TSH<0.5 mIU/L, on antithyroid medication), hyperthyroid untreated (TSH<0.5 mIU/L, not on antithyroid medication), and hyperthyroid overtreated (TSH>5.0 mIU/L, on antithyroid medication). Serum TSH data were obtained from the Decision Support System National Data Extracts Laboratory Results file.
28
Medication data were obtained from VA pharmacy dispensation records. 29 Outcome Ascertainment Our outcome of interest was all-cause mortality. Patients were followed for outcomes starting the day after TSH measurement. Patients were censored for kidney transplantation, loss to follow-up, or the last date of available follow-up data (July 26, 2013), whichever occurred first. All-cause mortality data, censoring events, and associated dates were obtained from VA Vital Status File, which has been observed to have a sensitivity and specificity of 98.3% and 99.8%, respectively, in comparison to the National Death Index. 30 Sociodemographic, Comorbidity, Medication, and Laboratory Covariates Patients' baseline sociodemographic information (age, sex, race, ethnicity) was obtained from the VA Corporate Data Warehouse and from Medicare through the VA-Medicare data merge project 31 as previously described. [23] [24] [25] [26] Information about comorbidities was extracted from the VA Inpatient and Outpatient Medical SAS data sets using International Classification of Diseases, Ninth Revision diagnostic and procedure codes and Current Procedural Terminology codes. 32 Charlson comorbidity index scores were estimated using the Deyo modification for administrative data sets without including kidney disease. 33 Body mass index data were obtained from the VA Vital Status File. Laboratory data except serum creatinine were obtained from the Decision Support System National Data Extracts Laboratory Results files. 28 VA Corporate Data Warehouse LabChem data files were used to extract serum creatinine data. 34 Using serum creatinine and demographic data, eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. 35 
Statistical Analyses
We estimated the association between thyroid status and mortality using Cox proportional hazard models with 5 hierarchical levels of covariate adjustment. In time-dependent analyses, all laboratory data were examined as timedependent covariates: We a priori defined the expanded case-mix adjusted model as our preferred model, which included core sociodemographic measures and other confounders of the association between thyroid status and mortality. There were no missing data for covariates in the case-mix and expanded case-mix models (eg, age, sex, race, ethnicity, and comorbidities), whereas there were varying degrees of missing data for laboratory variables including albumin (17.3%), hemoglobin (15.4%), triglycerides (13.7%), cholesterol (13.6%), and low-density lipoprotein (18.9%; proportions shown represent missing baseline data). Hence, further adjustments for potential confounders in expanded case-mix þ laboratory and expanded case-mix þ laboratory þ thyroid medication models (which have the potential for inherent selection bias due to missing data) were conducted as sensitivity analyses. In these analyses, missing data were handled using multiple imputation.
To address differential quality of care as a potential confounder of thyroid statusmortality associations, we conducted a series of sensitivity analyses that incrementally adjusted for proxies of provider attentiveness/adherence with health care recommendations and patient medical compliance, in addition to covariates in the expanded casemix þ laboratory þ thyroid medication model: (1) angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or statin prescription within 1 year of study entry; (2) receipt of influenza vaccination within 1 year of study entry; or (3) patient's history of noncompliance with medical treatment ascertained by International Classification of Diseases, Ninth Revision code V15.81.
We additionally conducted subgroup analyses of thyroid status (categorized as TSH levels of >5.0, 0.5-5.0 [euthyroid], and <0.5 mIU/L) across clinically relevant categories of sociodemographic characteristics, comorbidity status, and laboratory measures. Proportional hazards assumptions were confirmed by graphical analysis. Analyses and figures were generated using SAS version 9.4 (SAS Institute Inc), Stata version 14 (Stata Corporation), and SigmaPlot version 12.5 (Systat Software).
RESULTS
Study Population
Among 227,426 patients who met eligibility criteria (Supplemental Figure 1 , available online at http://www.mayoclinicproceedings. org), 6.4%, 90.0%, and 3.4% of patients had baseline TSH levels of more than 5.0, 0.5 to 5.0 (euthyroid), and less than 0.5 mIU/L, respectively. The mean AE SD, median (IQR), and minimum-maximum of observed baseline TSH values were 2.7AE6.7, 1.9 (1.2-2.8), and 0.001-531.5 mIU/L, respectively. Compared with patients whose baseline TSH levels were less than 0.5 mIU/L or in the euthyroid range, those with TSH levels of more than 5.0 mIU/L were older, more likely to be non-Hispanic white, and less likely to be non-Hispanic black; were more likely to have cardiovascular disease and less likely to have hypertension; were more likely to have higher total cholesterol and triglyceride levels; and were less likely to be prescribed an ACEI or ARB within 1 year of study entry (Table) . Compared with patients who were euthyroid at baseline, those who were hyperthyroid and hypothyroid were also more likely to have CHF and less likely to have hyperlipidemia. Baseline characteristics of patients categorized by finer gradations of TSH are presented in Supplemental Table 1 (available online at http://www.mayoclinicproceedings.org).
Thyroid Status and Mortality
Patients contributed a total of 1,134,837 patientyears of follow-up during which time 67,706 allcause deaths occurred. Median (IQR) at-risk time was 65 (38-83) months. In analyses of baseline thyroid status adjusted for expanded casemix covariates, TSH levels of more than 5.0 and less than 0.5 mIU/L were each associated with higher mortality risk (reference, euthyroidism): adjusted HRs (aHRs) (95% CI), 1.19 (1.15-1.24) and 1.18 (1.15-1.22), respectively ( Figure 1A ; Supplemental Table 2 , available online at http://www.mayoclinicproceedings. org). These associations were mildly attenuated after further adjustment for expanded casemix þ laboratory and expanded case-mix þ laboratory þ thyroid medication covariates, but remained statistically significant. Similarly, in analyses of time-dependent thyroid status, TSH levels of more than 5.0 and less than 0.5 mIU/L were each associated with higher mortality risk across all levels of adjustment ( Figure 1B ; Supplemental Table 2 ).
In sensitivity analyses of baseline TSH that included a 30-day lag period, we observed a robust association of TSH levels of more than 5.0 and less than 0.5 mIU/L with higher mortality risk in expanded case-mix models (reference, euthyroidism): aHRs (95% CI), 1.17 (1.13-1.22) and 1.17 (1.14-1.21), respectively (Supplemental Figure 2A and Supplemental Table 3 , available online at http://www. mayoclinicproceedings.org). In a subcohort of patients who had a baseline TSH in euthyroid range and a subsequent TSH measurement (N¼161,802), we identified 6027 and 3445 patients who had incident hypothyroidism and hyperthyroidism, respectively. Sensitivity Table 4 , available online at http://www. mayoclinicproceedings.org).
Granular Thyrotropin Levels and Mortality
A continuum of TSH increase and reduction from the reference range is recognized, with early or subclinical disease defined by an abnormal TSH with a reference range serum free thyroxine (FT4) measurement, which were not available for our study. In analyses that more granularly examined baseline TSH levels, we found that TSH categories of 3.0 mIU/L or more were associated with incrementally higher death risk in expanded case-mix models (reference, low-normal TSH): aHRs (95% CI), 1. Figure 3A and Supplemental Table 5 , available online at http://www.mayoclinicproceedings.org). These patterns of association persisted in analyses adjusted for expanded case-mix þ laboratory and expanded case-mix þ laboratory þ thyroid medication covariates. We also observed that TSH categories of less than 0.5 mIU/L were associated with higher mortality risk in expanded case-mix analyses: aHRs (95% CI), 1.21 (1.16-1.26) and 1.13 (1.02-1.25) for TSH levels in the subclinical-hyperthyroid and overthyperthyroid range, respectively. Associations between subclinical-hyperthyroid range TSH levels and mortality persisted in expanded case-mix þ laboratory and expanded casemix þ laboratory þ thyroid medication analyses. Similar associations were observed in analyses of baseline TSH that included a 30-day lag period (Supplemental Figure 2B and Supplemental Table 3 ).
In analyses of time-dependent TSH levels adjusted for expanded case-mix covariates, we A B Figure 3B and Supplemental Table 5 ). Associations remained significant in expanded case-mix þ laboratory and expanded case-mix þ laboratory þ thyroid medication adjusted analyses. We similarly observed that TSH levels in the subclinical-hyperthyroid range and overthyperthyroid range were associated with higher mortality: aHRs (95% CI), 1.27 (1.22-1.32) and 1.13 (1.02-1.25), respectively. Associations between subclinical-hyperthyroid range and overt-hyperthyroid range TSH levels and mortality persisted in expanded case-mix þ laboratory þ thyroid medication analyses (Supplemental Figure 3B and Supplemental Table 5 ).
In sensitivity analyses of baseline and timedependent TSH as continuous predictors of mortality using restricted cubic splines adjusted for expanded case-mix covariates, we observed a U-shaped association between TSH level and mortality, with a nadir of risk observed at TSH levels of approximately 1.7 to 2.1 mIU/L (Figure 2 ).
Adjustment for Quality-of-Care Indicators
To account for differential quality of care as a potential confounder of thyroid status-mortality associations, in sensitivity analyses we also examined several models that incrementally adjusted for proxies of provider attentiveness/adherence with health care recommendations and patient medical compliance, in addition to expanded case-mix þ laboratory þ thyroid medication covariates. Similar to expanded case-mix þ laboratory þ thyroid medication models, we observed that baseline and time-dependent TSH levels of more than 5.0 and less than 0.5 mIU/L were each associated with higher mortality risk in analyses that incrementally adjusted for ACEI/ARB or statin use, receipt of the influenza vaccination, and history of noncompliance (Supplemental Table 6 , available online at http://www.mayoclinicproceedings.org).
Following incremental adjustment for these quality-of-care indicators, we also found that associations of baseline TSH levels in the upper-normal, subclinical-hypothyroid, overthypothyroid, and subclinical-hyperthyroid ranges with mortality risk remained robust (Supplemental Table 7 , available online at http://www.mayoclinicproceedings.org). Following incremental adjustment for ACEI/ ARB or statin use, receipt of the influenza vaccination, and history of noncompliance, timedependent TSH levels in the upper-normal, subclinical-hypothyroid, overt-hypothyroid, and subclinical-hyperthyroid ranges, as well as in the overt-hyperthyroid range, were associated with higher mortality risk, similar to expanded case-mix þ laboratory þ thyroid medication covariates.
THYROID STATUS AND MORTALITY ACROSS CLINICALLY RELEVANT SUBGROUPS
We also examined the association between thyroid status (categorized as TSH levels of >5.0, 0.5-5.0 [euthyroidism], and <0.5 mIU/L; reference, euthyroidism) and mortality across clinically relevant subgroups. In baseline analyses adjusted for expanded case-mix covariates, we observed that hypothyroidism was associated with higher mortality across all subgroups except those who were female, and that hyperthyroidism was associated with higher mortality across all subgroups ( Figure 3A ; Supplemental vs lower BMI (<25 kg/m 2 ), and that stronger point estimates of the hyperthyroidism-mortality association were also observed among those with higher vs lower BMI.
In time-dependent analyses, we similarly observed that hypothyroidism was associated with higher mortality across all subgroups except those who were female, and that hyperthyroidism was associated with higher mortality across all subgroups ( Figure 3B ; Supplemental Table 9 , available online at http://www. mayoclinicproceedings.org). Interaction tests demonstrated that differences in estimates of the thyroid function-mortality association across subcategories were statistically significant for subgroups of age, race, underlying CHF, and BMI (P interactions¼<.001, <.001, .05, and .04, respectively; Figure 3B ), with stronger point estimates of hypothyroidism-mortality among those of younger (<60 years) vs older (!60 years) age, black vs nonblack race, with vs without CHF, and higher vs lower BMI, whereas stronger point estimates of the hyperthyroidismmortality association were observed among those of younger vs older age, nonblack vs black race, with vs without CHF, and higher vs lower BMI.
Thyroid Status, Medication Use, and Mortality In the overall cohort, 6.0% and less than 0.1% of patients were prescribed thyroid hormone supplementation or antithyroid medication, Analyses shown are expanded case-mix adjusted models, which included serum TSH level, age, sex, race, ethnicity, diabetes, congestive heart failure, cardiovascular disease, hypertension, hyperlipidemia, and Charlson comorbidity index. TSH ¼ thyrotropin.
respectively, at the time of study entry. In baseline analyses adjusted for expanded case-mix covariates, we observed that presumed untreated and undertreated hypothyroidism as well as untreated hyperthyroidism were associated with higher mortality risk (reference, spontaneous euthyroidism): aHRs (95% CI Table 10 ).
DISCUSSION
To our knowledge, this is the first study that has examined the association between thyroid status defined by repeated measures of serum TSH with mortality in patients with NDD-CKD. Among a large national cohort of US veterans with stage 3 CKD, granular examination of thyroid status showed that TSH levels in the high-normal (TSH !3.0 mIU/L) and hyperthyroid (TSH <0.5 mIU/L) ranges were independently associated with higher mortality risk. These associations persisted across multiple secondary and sensitivity analyses that considered baseline and time-dependent (ie, repeated) TSH measures (as a proxy of long-term and short-term associations, respectively); incrementally adjusted for potential confounders of the thyroid status-mortality associations across multivariable models, including quality-of-care indicators (eg, ACEI/ARB or statin use, receipt of the influenza vaccination, and history of noncompliance); and examined multiple clinically relevant subgroups. In sensitivity analyses that identified cases of incident thyroid disease, we also observed that TSH levels in the hypothyroid and hyperthyroid range were each associated with higher mortality risk. Our study also adds new knowledge to the field regarding the impact of thyroidmodulating therapy on the survival of patients with kidney disease. Although United States Renal Data System data show that levothyroxine is one of the most commonly prescribed medications among NDD-CKD and ESRD Medicare Part D beneficiaries, 36 there have been a paucity of studies examining the efficacy and safety of thyroid hormone replacement therapy in these populations. In a study of 2715 dialysis patients whose TSH levels and medication status were concurrently examined at study entry, we found that patients who were presumed to be hypothyroid treated-to-target had similar mortality vs patients who were spontaneously euthyroid, whereas those with undertreated or untreated hypothyroidism had higher mortality risk. 20 Although these limited data suggest benefit, thyroid hormone supplementation is a therapy that carries risk, given its (1) narrow toxic-totherapeutic window, 37 (2) augmentation of protein catabolism and protein-energy wasting 38 (ie, one of the strongest death predictors in patients with advanced CKD 39 ), and (3) potential to precipitate adverse cardiovascular sequelae (eg, atrial fibrillation and angina) with overtreatment. 18, 40 Using the national VA database with exceptional capture of prescription dispensation data over time, 29 in both baseline and timedependent analyses we found that untreated and undertreated hypothyroidism and untreated hyperthyroidism were each associated with higher mortality risk compared with spontaneous euthyroidism, whereas hypothyroidism treated-to-target (ie, TSH 0.5-5.0 mIU/L based on general population thresholds 17 ) had similar to slightly lower mortality risk. In timedependent analyses, there also appeared to be a trend between overtreated hypothyroidism and lower mortality risk, although only marginally decreased. Although mild medicationinduced thyrotoxicosis may be tolerated in the short-term in particular patient groups (ie, younger patients), further studies are needed to determine the long-term safety and effectiveness of thyroid-modulating therapy and specific TSH treatment targets.
As another noteworthy finding, our categorical analyses showed that incrementally higher TSH levels even in the high-normal range (TSH !3.0 mIU/L) were associated with increasingly higher mortality risk. Several other studies have similarly found that TSH levels exceeding 3.0 mIU/L are associated with higher mortality in dialysis patients. 8, 20 Even in the general population, there remains considerable controversy regarding the optimal upper limit of the target TSH range. Some experts recommend a therapeutic TSH upper limit of 2.5 to 3.0 mIU/L, 19,41,42 whereas others favor using upper TSH laboratory reference range values (w5.0 mIU/L). 43, 44 Given the potential risks of undertreatment and overtreatment, rigorous prospective studies are warranted to determine the optimal TSH target range in the CKD and ESRD populations.
Although thyroid dysfunction was linked with higher death risk across almost all subgroups, it bears mention that stronger hypothyroidism-mortality associations were particularly observed among subgroups of younger vs older age, black vs nonblack race, and those with vs without underlying CHF, corroborating emerging data in the general population. 45 Because some experts advise that the "normal" TSH range may differ according to age and race/ethnicity, 46 future studies are needed to more precisely define the ideal TSH thresholds among these CKD subgroups. Indeed, the increase in the upper reference for serum TSH with age may be especially relevant in the older NDD-CKD population, as most now recommend targeting a higher TSH for the elderly general population on levothyroxine therapy. 44 Furthermore, previous studies in the general population have suggested that those with CHF may have lower reserve with which to tolerate hemodynamic, volume, and electrophysiologic changes associated with hypothyroidism. Hence, patients with NDD-CKD who have structural heart disease may be particularly vulnerable to the ill effects of hypothyroidism, and future studies are needed to determine the specific mechanistic pathways linking thyroid perturbations and death in this population.
The strengths of our study include its examination of a large national cohort of patients with NDD-CKD with comprehensive availability of detailed patient-level information, including longitudinal laboratory and prescription data; a stable study population to examine the long-term and short-term associations of thyroid status, thyroid-modulating therapy, and outcomes; and reduced confounding by differential health care access. Several limitations of our study should be acknowledged. First, the indications for TSH testing in this cohort, a requirement for inclusion in the study, are unknown. However, this inclusion criterion was required of all patients irrespective of underlying thyroid status and thus should not impair the study's internal validity.
Furthermore, that the vast majority of our source population (82.3% of >3.5 million patients) underwent TSH testing provides further reassurance regarding the study's external validity. Second, the categories of thyroid status are generally classified on the basis of serum TSH and FT4 measurements. Given the sparsity of concurrent FT4 and free triiodothyronine measurements and their unclear reliability in advanced CKD (ie, peripheral conversion of T4-to-triiodothyronine is sensitive to nonthyroidal illness; routinely used FT4 assays are dependent on protein-hormone binding, and the presence of uremic toxins that interfere with protein-hormone binding may lead to spurious levels), 1,2,47-49 we elected to define thyroid status on the basis of TSH levels only. Although some aberrations of TSH have been described in the context of CKD, 50, 51 it remains a more robust metric of thyroid status particularly in the setting of underlying illness (ie, TSH levels typically remain normal in mildmoderate nonthyroidal illness, and become suppressed only in severe critically ill states 1,2,52 ), and serum TSH has been strongly associated with outcomes in our previous studies of dialysis patients. 8, 9, 20, 21 In addition, we observed persistent associations between TSH alterations and mortality in sensitivity analyses that incorporated a 30-day lag period and restricted analyses to incident cases of thyroid disease, hence excluding patients who died immediately after TSH measurement to minimize risk of observing a reverse-causal association (ie, severe illness may lead to TSH alterations as well as heightened mortality risk). Third, because our analyses included patients who were both incident (ie, treatmentnaive) and prevalent (ie, existing) users of thyroid hormone supplementation and antithyroid medications, we cannot exclude potential bias towards a protective effect of thyroidmodulating therapy (ie, patients receiving treatment at study entry may have been healthier than those who stopped or died using treatment before study entry because of adverse effects). 53 Fourth, given the retrospective nature of the study, we are not able to determine whether differential quality of care by providers or noncompliance with medical treatment may be a potential confounder of aberrant thyroid status and death risk. However, it should be noted that we observed robust thyroid status-mortality associations after incremental adjustment for proxies of quality of care. Finally, as with all observational studies, we cannot exclude the possibility of residual confounding, and our findings do not confirm a causal relationship between thyroid status, thyroidmodulating therapy, and mortality risk.
CONCLUSION
In conclusion, our study has found that higher TSH levels even in the high-normal range (!3.0 mIU/L) and lower TSH levels (<0.5 mIU/L) were independently associated with higher mortality risk in a national cohort of patients with NDD-CKD. We also observed that untreated and undertreated hypothyroidism and hyperthyroidism were associated with higher mortality compared with spontaneous euthyroidism, whereas hypothyroidism treated-totarget was associated with similar to slightly improved survival. At this time, rigorous prospective studies are needed to determine the precise optimal TSH range in patients with NDD-CKD, and whether treatment to these targets ameliorates mortality risk in this population.
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